Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Ribozyme and peptide-nucleic acid-based gene therapy
Autore:
Phylactou, LA;
Indirizzi:
Cyprus Inst Neurol & Genet, CY-1683 Nicosia, Cyprus Cyprus Inst Neurol & Genet Nicosia Cyprus CY-1683 Y-1683 Nicosia, Cyprus
Titolo Testata:
ADVANCED DRUG DELIVERY REVIEWS
fascicolo: 2-3, volume: 44, anno: 2000,
pagine: 97 - 108
SICI:
0169-409X(20001115)44:2-3<97:RAPAGT>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
HAMMERHEAD RIBOZYMES; MARFAN-SYNDROME; MESSENGER-RNA; IN-VITRO; ANTIONCOGENE RIBOZYMES; MALIGNANT PHENOTYPE; CATALYTIC ACTIVITY; MEDIATED REPAIR; LEUKEMIA-VIRUS; CELL-LINES;
Keywords:
hammerhead ribozyme; group I intron ribozyme; RNA cleavage; down-regulation; gene expression; RNA trans-splicing; RNA repair;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
70
Recensione:
Indirizzi per estratti:
Indirizzo: Phylactou, LA Cyprus Inst Neurol & Genet, 6 Int Airport Ave, CY-1683 Nicosia, Cyprus Cyprus Inst Neurol & Genet 6 Int Airport Ave Nicosia Cyprus CY-1683
Citazione:
L.A. Phylactou, "Ribozyme and peptide-nucleic acid-based gene therapy", ADV DRUG DE, 44(2-3), 2000, pp. 97-108

Abstract

The recent discovery that RNA can act as a catalyst, apart from carrying genetic information, has given a new dimension to the field of gene therapy and has come to act synergistically with antisense technology. Ribozymes can be used to down-regulate (by RNA cleavage) or repair (by RNA tr-ans-splicing) unwanted gene expression involved in disease. Hammerhead ribozymes have been used extensively to down-regulate gene expression in many diseases such as viral infections and cancer. Group I intron ribozymes on the other hand, have only been tried to repair inherited mutations but hold great promise for the future. Peptide nucleic acids (PNAs) technology is another new technology, which is currently been tried to block gene or RNA function. Gene therapy protocols need significant improvements in order to be used routinely in patients and hopefully, these new players should prove valuable toidentifying new therapies for several untreated diseases. (C) 2000 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 22:10:35